Biovalorization of Brewery Waste by Applying Anaerobic Digestion

In the food industry, the brewing sector holds a strategic economic position: in the year 2013, the beer production of the EU-28 was equal to 383,553,000 hL. The brewing process includes chemical and biochemical reactions and solid-liquid separations, involving the generation of various residues and by-products, among which the major two fractions are brewer’s spent grain (BSG), and exhausted brewery yeast (BY). Although until today their main use has been for animal feed, in recent years, several studies have investigated the application of anaerobic digestion in order to revalue the brewery wastes. In this work, specific methane production (SMP) and first-order solubilisation (disintegration+ hydrolysis) rates (ksol) for BSG and BY were evaluated. Biomethanation tests were performed in 5-L fed-batch stirred reactors at several substrate/inoculum ratios. The obtained SMP ranged from 0.255 L CH4 g–1 COD for exhausted brewery yeast to 0.284 L CH4 g–1 COD for brewer’s spent grain. The estimated ksol values ranged from 0.224 d–1 for BSG to 0.659 d–1 for BY

Operation of an AnMBR for winery wastewater treatment at low temperature

The growing concern in the development of new intensive and compact technologies is due to the more and more stringent regulations regarding waste disposal and the aim of reducing energy and space requirements, particularly in industrial facilities as wineries. During vintage, the high organic load of the winery wastewater favours the application of mesophilic anaerobic processes to convert the organic matter into biogas. However, when loads are low in winter season, the anaerobic digestion should be carried out at room temperature. The main goal of this work is to operate an anaerobic membrane bioreactor (AnMBR)fed with synthetic winery wastewater at low temperatures (15\u1d52C and 25\u1d52C) evaluating its methanogenic activity and comparing it with the operation at mesophilic conditions

Multi-regional Sequencing Analysis Reveals Extensive Genetic Heterogeneity in Gastric Tumors from Latinos

Gastric cancer is a leading cause of cancer mortality and health disparities in Latinos. We evaluated gastric intratumoral heterogeneity using multiregional sequencing of >700 cancer genes in 115 tumor biopsies from 32 patients, 29 who were Latinos. Analyses focused on comparisons with The Cancer Genome Atlas (TCGA) and on mutation clonality, druggability, and signatures. We found that only approximately 30% of all mutations were clonal and that only 61% of the known TCGA gastric cancer drivers harbored clonal mutations. Multiple clonal mutations were found in new candidate gastric cancer drivers such as EYS, FAT4, PCDHA1, RAD50, EXO1, RECQL4, and FSIP2. The genomically stable (GS) molecular subtype, which has the worse prognosis, was identified in 48% of our Latino patients, a fraction that was >2.3-fold higher than in TCGA Asian and White patients. Only a third of all tumors harbored clonal pathogenic mutations in druggable genes, with most (93%) GS tumors lacking actionable clonal mutations. Mutation signature analyses revealed that, in microsatellite-stable (MSS) tumors, DNA repair mutations were common for both tumor initiation and progression, while tobacco, POLE, and inflammation signatures likely initiate carcinogenesis. MSS tumor progression was likely driven by aging- and aflatoxin-associated mutations, as these latter changes were usually nonclonal. In microsatellite-unstable tumors, nonclonal tobacco-associated mutations were common. Our study, therefore, contributed to advancing gastric cancer molecular diagnostics and suggests clonal status is important to understanding gastric tumorigenesis. Our findings of a higher frequency of a poor prognosis associated molecular subtype in Latinos and a possible new aflatoxin gastric cancer etiology also advance cancer disparities research.SignificanceOur study contributes to advancing our knowledge of gastric carcinogenesis, diagnostics, and cancer health disparities

Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort

Objectives: This study aimed to assess the real use of cefazolin for methicillin-susceptible Staphylococcus aureus (MSSA) infective endocarditis (IE) in the Spanish National Endocarditis Database (GAMES) and to compare it with antistaphylococcal penicillin (ASP). Methods: Prospective cohort study with retrospective analysis of a cohort of MSSA IE treated with cloxacillin and/or cefazolin. Outcomes assessed were relapse; intra-hospital, overall, and endocarditis-related mortality; and adverse events. Risk of renal toxicity with each treatment was evaluated separately. Results: We included 631 IE episodes caused by MSSA treated with cloxacillin and/or cefazolin. Antibiotic treatment was cloxacillin, cefazolin, or both in 537 (85%), 57 (9%), and 37 (6%) episodes, respectively. Patients treated with cefazolin had significantly higher rates of comorbidities (median Charlson Index 7, P <0.01) and previous renal failure (57.9%, P <0.01). Patients treated with cloxacillin presented higher rates of septic shock (25%, P = 0.033) and new-onset or worsening renal failure (47.3%, P = 0.024) with significantly higher rates of in-hospital mortality (38.5%, P = 0.017). One-year IE-related mortality and rate of relapses were similar between treatment groups. None of the treatments were identified as risk or protective factors. Conclusion: Our results suggest that cefazolin is a valuable option for the treatment of MSSA IE, without differences in 1-year mortality or relapses compared with cloxacillin, and might be considered equally effective